Servier’s Oncology Strategy Pays Off As Vorasidenib Hits Bullseye In Pivotal Glioma Trial
Asset Acquired Under $1.8bn Agios Deal
The French firm’s vorasidenib, obtained via a 2020 deal with Agios, has met the primary endpoint in a pivotal glioma trial, according to interim data, validating its strategic focus on the oncology space.
